Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

476 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis.
Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, Koc Y, Ciceri F, Finke J, Labussière-Wallet H, Cascon MJP, Verbeek M, Rambaldi A, Cornelissen JJ, Chevallier P, Radia R, Nagler A, Fegueux N, Gluckman E, de Witte T, Kröger N. Robin M, et al. Among authors: verbeek m. Biol Blood Marrow Transplant. 2019 Jan;25(1):114-120. doi: 10.1016/j.bbmt.2018.08.026. Epub 2018 Aug 30. Biol Blood Marrow Transplant. 2019. PMID: 30172776 Free article.
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, Verbeek M, Fischer J, Otten V, Schmickl M, Maas-Bauer K, Finke J, Peschel C, Duyster J, Poeck H, Zeiser R, von Bubnoff N. Spoerl S, et al. Among authors: verbeek m. Blood. 2014 Jun 12;123(24):3832-42. doi: 10.1182/blood-2013-12-543736. Epub 2014 Apr 7. Blood. 2014. PMID: 24711661 Free article.
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N. Zeiser R, et al. Among authors: verbeek m. Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31. Leukemia. 2015. PMID: 26228813 Free PMC article.
Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU. Neuenhahn M, et al. Among authors: verbeek m. Leukemia. 2017 Oct;31(10):2161-2171. doi: 10.1038/leu.2017.16. Epub 2017 Jan 16. Leukemia. 2017. PMID: 28090089 Clinical Trial.
Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.
Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P. Sahebi F, et al. Among authors: verbeek m. Biol Blood Marrow Transplant. 2019 Feb;25(2):335-342. doi: 10.1016/j.bbmt.2018.09.018. Epub 2018 Sep 20. Biol Blood Marrow Transplant. 2019. PMID: 30243581 Free PMC article. Clinical Trial.
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M. Beelen DW, et al. Among authors: verbeek m. Lancet Haematol. 2020 Jan;7(1):e28-e39. doi: 10.1016/S2352-3026(19)30157-7. Epub 2019 Oct 9. Lancet Haematol. 2020. PMID: 31606445 Clinical Trial.
Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation.
Wagner-Drouet E, Teschner D, Wolschke C, Janson D, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, Hilgendorf I, von Lilienfeld-Toal M, Klein S, Heidenreich D, Kreil S, Verbeek M, Grass S, Ditschkowski M, Gromke T, Koch M, Lindemann M, Hünig T, Schmidt T, Rascle A, Guldan H, Barabas S, Deml L, Wagner R, Wolff D. Wagner-Drouet E, et al. Among authors: verbeek m. Haematologica. 2021 Feb 1;106(2):363-374. doi: 10.3324/haematol.2019.229252. Haematologica. 2021. PMID: 31879324 Free PMC article.
Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation.
Heilig CE, Badoglio M, Labopin M, Fröhling S, Secondino S, Heinz J, Nicolas-Virelizier E, Blaise D, Korenbaum C, Santoro A, Verbeek M, Krüger W, Siena S, Passweg JR, Di Nicola M, Rifón J, Dreger P, Koehl U, Chabannon C, Pedrazzoli P. Heilig CE, et al. Among authors: verbeek m. ESMO Open. 2020 Oct;5(5):e000860. doi: 10.1136/esmoopen-2020-000860. ESMO Open. 2020. PMID: 33097652 Free PMC article.
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
Rodríguez-Arbolí E, Labopin M, Eder M, Brecht A, Blau IW, Huynh A, Forcade E, Tischer J, Bethge W, Bondarenko S, Verbeek M, Bulabois CE, Einsele H, Stölzel F, Savani B, Spyridonidis A, Bazarbachi A, Giebel S, Brissot E, Schmid C, Nagler A, Mohty M. Rodríguez-Arbolí E, et al. Among authors: verbeek m. Bone Marrow Transplant. 2022 Jun;57(6):934-941. doi: 10.1038/s41409-022-01611-y. Epub 2022 Apr 7. Bone Marrow Transplant. 2022. PMID: 35393528
Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt HC, Finke J, Franke GN, Ciceri F, Verbeek M, Blau IW, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani BN, Mohty M. Nagler A, et al. Among authors: verbeek m. Bone Marrow Transplant. 2022 Jul;57(7):1116-1123. doi: 10.1038/s41409-022-01693-8. Epub 2022 Apr 30. Bone Marrow Transplant. 2022. PMID: 35501565
476 results